

Rabbit Anti-Human SC5b-9 Neo IgG

For **Research Use Only**. Not for use in diagnostic procedures

Background

Activation of the terminal complement pathway is the result of activation of any of the three pathways in the complement system: the classical, alternative and lectin pathways. In this process, complement protein C5 is cleaved to C5b and may then interact sequentially with complement proteins C6, C7, C8 and C9 forming the terminal complement complex (TCC). In the presence of a membrane, these complexes can form transmembrane pores causing complement mediated cytolysis. In the absence of a target membrane, the TCC binds to naturally occurring regulatory serum proteins and the resulting products are commonly called SC5b-9.

Characterization

Highly purified SC5b-9 was isolated and used to immunize rabbits. The Anti-Human SC5b-9 Neoantigen IgG fraction is stringently absorbed with normal complement proteins to be monospecific for the SC5b-9 neoantigen. The purified IgG Fraction was tested by immunodiffusion and determined to be monospecific for the SC5b-9 neoantigen.

Applications

Applications of the Anti-Human SC5b-9 Neoantigen IgG Fraction have been evaluated, and include immunodiffusion and ELISA. Testing by Western Blot is not recommended.

Specifications

- Volume/vial: .25 mL
- Storage: 2°C to 8°C* (≤ 30 days)
- Form: Purified IgG Fraction
- Preservative: ≤ 0.1% Sodium Azide

Species Cross Reactivity:

Species cross reactivity not tested

*For long-term storage (> 30 days), aliquot and store at ≤ -20°C. Avoid repeated freeze-thaw.

Rabbit Anti-Human SC5b-9 Neo IgG – Cat. #A317

Also available:

MicroVue SC5b-9 Plus EIA – Cat. #A020 (RUO)
Cat. #A029 (CE)

Anti-human SC5b-9 (TCC neoantigen)
Monoclonal Antibody – Cat. #A239